Botox Injection denials: 58.0% overturned by independent reviewers
In 517 California IMR decisions from 2001 to 2026, reviewers overturned the plan 300 times (58.0%). In the last five years: 71.7% of 92. Denials reach IMR only when a member appeals all the way; read the caveats below before generalising.
By diagnosis
| Diagnosis category | Decisions | Overturned | Last 5 years |
|---|---|---|---|
| CNS/ Neuromusc Dis | 335 | 62.4% | 83.0% of 47 |
| Orth/Musculoskeletal | 88 | 48.9% | 50.0% of 18 |
| Skin Disorders | 19 | 84.2% | 83.3% of 6 |
| GU/ Kidney Disorder | 18 | 44.4% | 57.1% of 7 |
| Digestive System/ GI | 9 | 11.1% | 33.3% of 3 |
| Chron Pain Synd | 9 | 44.4% | — |
| OB-GYN/ Pregnancy | 7 | 42.9% | — |
By year (last five)
| Year | Decisions | Overturned |
|---|---|---|
| 2021 | 21 | 81.0% |
| 2022 | 13 | 76.9% |
| 2023 | 8 | 37.5% |
| 2024 | 17 | 52.9% |
| 2025 | 29 | 82.8% |
| 2026 | 4 | 75.0% |
What the findings mention
| What the findings mention | Decisions | Overturned | All decisions here |
|---|---|---|---|
| Published evidence citedThe findings refer to peer-reviewed or published evidence. | 169 | 55.6% | 58.0% |
| Prior therapies failedThe findings mention treatments that were tried without adequate response. | 161 | 80.1% | 58.0% |
| Experimental or investigationalThe findings discuss whether the treatment is experimental. | 86 | 50.0% | 58.0% |
| Step therapy or fail-firstThe findings mention a fail-first requirement. | 64 | 70.3% | 58.0% |
| Records did not supportThe findings say the documentation did not show what was needed (usually an upheld denial). | 55 | 5.5% | 58.0% |
| FDA approval or off-label use discussedThe findings discuss the FDA label status of the treatment. | 49 | 69.4% | 58.0% |
| Alternatives contraindicatedThe findings mention a contraindication to the plan's preferred option. | 29 | 65.5% | 58.0% |
| Guidelines or criteria citedThe findings cite guidelines, criteria or a standard of care. | 9 | 66.7% | 58.0% |
| Urgent or emergencyThe findings mention urgency. | 6 | 100.0% | 58.0% |
Keyword matches on the reviewer’s findings, not causes. A tag that appears mostly in overturned decisions is worth documenting in an appeal; it is not a guarantee.
From recent overturned decisions
“The physician reviewer found that a patient has requested reimbursement and prospective authorization and coverage for onabotulinumtoxinA (Botox) injections consisting of a total of 200 units per treatment provided previously and going forward.The treatment of severe and/or refractory primary axillary hyperhidrosis must be individualized based on clinical findings and presentation. Medical literature supports the use of botulinum toxin A as …”
“The physician reviewer found that Nature of Statutory Criteria/Case Summary: A patient has requested authorization and coverage for Botox treatments.The records document that the patient has been diagnosed with chronic migraines. The patient reports headaches occurring three to four days per week, lasting two to seven hours with treatment and at times persisting throughout the day without treatment. The records …”
“The physician reviewer found that Nature of Statutory Criteria/Case Summary: A patient has requested authorization and coverage for Botox injections. Botox is an option for the treatment of various kinds of migraines, including chronic, episodic, unilateral, and vestibular types, that can reduce the frequency of migraine attacks per month and diminish the severity of pain. Per the medical records, the …”
- California only: these are decisions by independent reviewers under California's IMR program (plans regulated by the Department of Managed Health Care). Other states and self-funded employer plans use different reviewers and rules.
- Selection: only denials that a member took all the way to IMR appear. Most denials are never appealed, and the ones that reach an external reviewer are not a random sample.
- Overturned means the reviewer disagreed with the plan; it does not mean the treatment worked or that a similar request will be approved.
- Argument tags are keyword matches on the reviewer's findings. They describe what the findings mention, not why the case was decided.
- Categories are DMHC's own labels (treatment sub-category and diagnosis category); 'Other' is a catch-all and is excluded from rankings.
Source: California Department of Managed Health Care, Independent Medical Review (IMR) Determinations, Trend (CHHS Open Data). Public California government data; Apellica's aggregates and tags are CC BY 4.0.
Questions
How often were Botox Injection denials overturned?
In 517 California IMR decisions from 2001 to 2026, reviewers overturned the plan 300 times (58.0%). In the last five years: 71.7% of 92.
What did the reviewers' findings mention in overturned cases?
The table on this page counts keyword matches in the findings: prior therapies tried, contraindications, guidelines cited, published evidence, whether the records supported the request. They describe what the findings say, not why the case was decided.
Does a California IMR result apply to my plan?
Only California plans regulated by the Department of Managed Health Care go to IMR. Other states and self-funded employer plans use different reviewers, but the reasoning is the same kind: criteria, documentation and alternatives. Use the findings as a guide to what to document.
Related: California appeal rights · California external-review reversal rate · The levers library · CSV
Independent reviewers reverse plans when the record answers the criteria. Upload the denial letter; a senior reviewer reads it within 24 hours and tells you in writing whether it can be appealed and how. $0 upfront, 10% of what is recovered, nothing if we do not recover. Not a law firm.